[
  {
    "objectID": "article.html",
    "href": "article.html",
    "title": "SoCO Journal Club",
    "section": "",
    "text": "Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study"
  },
  {
    "objectID": "article.html#introduction",
    "href": "article.html#introduction",
    "title": "SoCO Journal Club",
    "section": "Introduction",
    "text": "Introduction"
  },
  {
    "objectID": "article.html#tables-and-figures",
    "href": "article.html#tables-and-figures",
    "title": "SoCO Journal Club",
    "section": "Tables and Figures",
    "text": "Tables and Figures"
  },
  {
    "objectID": "article/Discussion/index.html",
    "href": "article/Discussion/index.html",
    "title": "Discussion",
    "section": "",
    "text": "← Previous"
  },
  {
    "objectID": "article/Discussion/index.html#paulsunandana",
    "href": "article/Discussion/index.html#paulsunandana",
    "title": "Discussion",
    "section": "",
    "text": "← Previous"
  },
  {
    "objectID": "article/Figure_1/index.html",
    "href": "article/Figure_1/index.html",
    "title": "Figure 1",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Figure_1/index.html#karamross",
    "href": "article/Figure_1/index.html#karamross",
    "title": "Figure 1",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Figure_2a/index.html",
    "href": "article/Figure_2a/index.html",
    "title": "Figure 2A",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Figure_2a/index.html#reedade",
    "href": "article/Figure_2a/index.html#reedade",
    "title": "Figure 2A",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Figure_2b/index.html",
    "href": "article/Figure_2b/index.html",
    "title": "Figure 2B",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Figure_2b/index.html#reedade",
    "href": "article/Figure_2b/index.html#reedade",
    "title": "Figure 2B",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Introduction/index.html",
    "href": "article/Introduction/index.html",
    "title": "Introduction",
    "section": "",
    "text": "Monotherapy Nivolumab Schema\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNivolumab Plus Ipilimumab Schema\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEfficacy of ICI in MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\nImmunotherapy for Merkel Cell Carcinoma\n\n\n\n\n\nTherapy\nStudy\nLine of Therapy\nN\nObjective Response (%)\nMedian PFS (months)\nMedian OS (months)\n\n\n\n\nAvelumab\nJavelin\n1\n116\n40\n4.1\n20.3\n\n\nPembrolizumab\nCITN-09\n1\n50\n58\n16.8\nNR\n\n\nNivolumab\nCheckMate-358\n1\n15\n73\n24.8\nNR\n\n\nNivolumab + Ipilimumab\nCheckMate-358\n1\n33\n64\n15.4\n35.58\n\n\nNivolumab + Ipilimumab\nMoffitt IST\n1\n13\n100\nNR\nNR\n\n\nRetifanlimab\nPOD1UM-201\n1\n65\n52\nNA\nNA\n\n\nAggregate\nAggregate\n1\n292\n53\nNA\nNA\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEfficacy of ICI in MCC, Ordered By Sample Size\n\n\n\n\n\n\n\n\n\n\n\n\n\nImmunotherapy for Merkel Cell Carcinoma\n\n\n\n\n\nTherapy\nStudy\nLine of Therapy\nN\nObjective Response (%)\nMedian PFS (months)\nMedian OS (months)\n\n\n\n\nNivolumab + Ipilimumab\nMoffitt IST\n1\n13\n100\nNR\nNR\n\n\nNivolumab\nCheckMate-358\n1\n15\n73\n24.8\nNR\n\n\nNivolumab + Ipilimumab\nCheckMate-358\n1\n33\n64\n15.4\n35.58\n\n\nPembrolizumab\nCITN-09\n1\n50\n58\n16.8\nNR\n\n\nRetifanlimab\nPOD1UM-201\n1\n65\n52\nNA\nNA\n\n\nAvelumab\nJavelin\n1\n116\n40\n4.1\n20.3\n\n\n\n\n\n\n\n\n\n\n\n\nNext →"
  },
  {
    "objectID": "article/Introduction/index.html#paul",
    "href": "article/Introduction/index.html#paul",
    "title": "Introduction",
    "section": "",
    "text": "Next →"
  },
  {
    "objectID": "article/Table_1/index.html",
    "href": "article/Table_1/index.html",
    "title": "Table 1",
    "section": "",
    "text": "Notes\n\n\n\n\n\nThe NIVO monotherapy cohort had a numerically lower proportion of patients with adverse prognostic factors than the combination treatment cohort, including age ≥65 years (60% v 74%, respectively), an ECOG PS of 1 (40% v 63%), stage IV disease (80% v 93%), virus-negative MCC (28% v 42%), and tumor burden at baseline (median, 55.5 v 72 mm; Table 1). However, the monotherapy cohort had a higher proportion of patients who had previously received systemic therapy for MCC than the combination cohort (40% v 23%). Among those who had received previous systemic therapy, most had received chemotherapy\n\n\n\n\n← Previous Next →"
  },
  {
    "objectID": "article/Table_1/index.html#ade-adamsonsonia",
    "href": "article/Table_1/index.html#ade-adamsonsonia",
    "title": "Table 1",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Table_2/index.html",
    "href": "article/Table_2/index.html",
    "title": "Table 2",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Table_2/index.html#sujustine",
    "href": "article/Table_2/index.html#sujustine",
    "title": "Table 2",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Table_3/index.html",
    "href": "article/Table_3/index.html",
    "title": "Table 3",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Table_3/index.html#justinesong",
    "href": "article/Table_3/index.html#justinesong",
    "title": "Table 3",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "article/Table_4/index.html",
    "href": "article/Table_4/index.html",
    "title": "Table 4",
    "section": "",
    "text": "Notes\n\n\n\n\n\nNine of 25 patients (36%) in the NIVO cohort and 21 of 42 patients (50%) in the NIVO 1 IPI cohort required concomitant immunosuppressant use because of an immune-related adverse event.\nThere was one treatment-related death in each cohort: pneumonitis in the NIVO cohort and GI motility disorder because of enteric neuropathy in the NIVO 1 IPI cohort, the latter of which has been reported elsewhere.\nAmong patients who discontinued treatment for any reason other than disease progression, one of 18 patients (5.5%) in the NIVO cohort and two of 28 patients (7.1%) in the NIVO 1 IPI cohort subsequently experienced disease pro- gression.\n\n\n\n\n← Previous Next →"
  },
  {
    "objectID": "article/Table_4/index.html#paulsu",
    "href": "article/Table_4/index.html#paulsu",
    "title": "Table 4",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "\nSociety of Cutaneous Oncology Journal Club April 10, 2025\n",
    "section": "",
    "text": "Society of Cutaneous Oncology Journal ClubApril 10, 2025\n\n\n\n\n\nAgenda\n\n\n\nBrief Introductions\n\n\nAcademic participants please put the following in the chat:\n\n\nName, affiliated hospital/institution, role\n\n\n\n\nBMS\n\n\nBrief introductions on screen\n\n\n\n\n\n\n4th International MCC Symposium \n\n\nPerspectives on the Science\n\n\nSoCo JC Timeline\n\n\nPre-JC Survey\n\n\nMain Paper\n\n\nPost-JC Survey\n\n\nDiscussion\n\n\n\n\n\n↑ Top"
  },
  {
    "objectID": "SoCO_Survey.html#pre-journal-club-survey",
    "href": "SoCO_Survey.html#pre-journal-club-survey",
    "title": "\nPre Journal Club Survey\n",
    "section": "Pre Journal Club Survey",
    "text": "Pre Journal Club Survey\n\n\n\n\n\n\n\n\n\n\n\nRole\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nExperience With Merkel Cell Carcinoma\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nExperience With Nivolumab Plus Ipilimumab in MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTreatment Recommendations #1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTreatment Recommendations #2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCoverage for Ipi/Nivo in MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNCCN Guidelines for Ipi/Nivo in MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIpilimumab Labeling for MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIpilimumab Labeling for MCC Warranted\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNivo Plus Ipi Dosing in First-Line MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNivo Plus Ipi Dosing in Second-Line MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "pre_jc_survey/Ipi_nivo_rx_yn/index.html",
    "href": "pre_jc_survey/Ipi_nivo_rx_yn/index.html",
    "title": "Experience With Nivolumab Plus Ipilimumab in MCC",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/barriers/index.html",
    "href": "pre_jc_survey/barriers/index.html",
    "title": "Barriers to Ipi/Nivo",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/case_1/index.html",
    "href": "pre_jc_survey/case_1/index.html",
    "title": "Treatment Recommendations #1",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/case_2/index.html",
    "href": "pre_jc_survey/case_2/index.html",
    "title": "Treatment Recommendations #2",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/coverage_denied/index.html",
    "href": "pre_jc_survey/coverage_denied/index.html",
    "title": "Coverage for Ipi/Nivo in MCC",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/experience/index.html",
    "href": "pre_jc_survey/experience/index.html",
    "title": "Experience With Merkel Cell Carcinoma",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/labeling/index.html",
    "href": "pre_jc_survey/labeling/index.html",
    "title": "Ipilimumab Labeling for MCC",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/labeling_warranted/index.html",
    "href": "pre_jc_survey/labeling_warranted/index.html",
    "title": "Ipilimumab Labeling for MCC Warranted",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/nccn_guidelines/index.html",
    "href": "pre_jc_survey/nccn_guidelines/index.html",
    "title": "NCCN Guidelines for Ipi/Nivo in MCC",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/role/index.html",
    "href": "pre_jc_survey/role/index.html",
    "title": "Role",
    "section": "",
    "text": "Next →"
  },
  {
    "objectID": "pre_jc_survey/first_line/index.html",
    "href": "pre_jc_survey/first_line/index.html",
    "title": "Nivo Plus Ipi Dosing in First-Line MCC",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "pre_jc_survey/second_line/index.html",
    "href": "pre_jc_survey/second_line/index.html",
    "title": "Nivo Plus Ipi Dosing in Second-Line MCC",
    "section": "",
    "text": "← Previous Next →"
  },
  {
    "objectID": "Pre_JC_Survey.html#pre-journal-club-survey",
    "href": "Pre_JC_Survey.html#pre-journal-club-survey",
    "title": "\nPre Journal Club Survey\n",
    "section": "Pre Journal Club Survey",
    "text": "Pre Journal Club Survey\n\n\n\n\n\n\n\n\n\n\n\nRole\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nExperience With Merkel Cell Carcinoma\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nExperience With Nivolumab Plus Ipilimumab in MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTreatment Recommendations #1\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTreatment Recommendations #2\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCoverage for Ipi/Nivo in MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNCCN Guidelines for Ipi/Nivo in MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIpilimumab Labeling for MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIpilimumab Labeling for MCC Warranted\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNivo Plus Ipi Dosing in First-Line MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNivo Plus Ipi Dosing in Second-Line MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "article/Introduction/index.html#shailenderpaul",
    "href": "article/Introduction/index.html#shailenderpaul",
    "title": "Introduction",
    "section": "",
    "text": "Monotherapy Nivolumab Schema\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNivolumab Plus Ipilimumab Schema\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEfficacy of ICI in MCC\n\n\n\n\n\n\n\n\n\n\n\n\n\nImmunotherapy for Merkel Cell Carcinoma\n\n\n\n\n\nTherapy\nStudy\nLine of Therapy\nN\nObjective Response (%)\nMedian PFS (months)\nMedian OS (months)\n\n\n\n\nAvelumab\nJavelin\n1\n116\n40\n4.1\n20.3\n\n\nPembrolizumab\nCITN-09\n1\n50\n58\n16.8\nNR\n\n\nNivolumab\nCheckMate-358\n1\n15\n73\n24.8\nNR\n\n\nNivolumab + Ipilimumab\nCheckMate-358\n1\n33\n64\n15.4\n35.58\n\n\nNivolumab + Ipilimumab\nMoffitt IST\n1\n13\n100\nNR\nNR\n\n\nRetifanlimab\nPOD1UM-201\n1\n65\n52\nNA\nNA\n\n\nAggregate\nAggregate\n1\n292\n53\nNA\nNA\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEfficacy of ICI in MCC, Ordered By Sample Size\n\n\n\n\n\n\n\n\n\n\n\n\n\nImmunotherapy for Merkel Cell Carcinoma\n\n\n\n\n\nTherapy\nStudy\nLine of Therapy\nN\nObjective Response (%)\nMedian PFS (months)\nMedian OS (months)\n\n\n\n\nNivolumab + Ipilimumab\nMoffitt IST\n1\n13\n100\nNR\nNR\n\n\nNivolumab\nCheckMate-358\n1\n15\n73\n24.8\nNR\n\n\nNivolumab + Ipilimumab\nCheckMate-358\n1\n33\n64\n15.4\n35.58\n\n\nPembrolizumab\nCITN-09\n1\n50\n58\n16.8\nNR\n\n\nRetifanlimab\nPOD1UM-201\n1\n65\n52\nNA\nNA\n\n\nAvelumab\nJavelin\n1\n116\n40\n4.1\n20.3\n\n\n\n\n\n\n\n\n\n\n\n\nNext →"
  },
  {
    "objectID": "article/Table_1/index.html#adesonia",
    "href": "article/Table_1/index.html#adesonia",
    "title": "Table 1",
    "section": "",
    "text": "Notes\n\n\n\n\n\nThe NIVO monotherapy cohort had a numerically lower proportion of patients with adverse prognostic factors than the combination treatment cohort, including age ≥65 years (60% v 74%, respectively), an ECOG PS of 1 (40% v 63%), stage IV disease (80% v 93%), virus-negative MCC (28% v 42%), and tumor burden at baseline (median, 55.5 v 72 mm; Table 1). However, the monotherapy cohort had a higher proportion of patients who had previously received systemic therapy for MCC than the combination cohort (40% v 23%). Among those who had received previous systemic therapy, most had received chemotherapy\n\n\n\n\n← Previous Next →"
  },
  {
    "objectID": "article/Table_4/index.html#rossvishal",
    "href": "article/Table_4/index.html#rossvishal",
    "title": "Table 4",
    "section": "",
    "text": "Notes\n\n\n\n\n\nNine of 25 patients (36%) in the NIVO cohort and 21 of 42 patients (50%) in the NIVO 1 IPI cohort required concomitant immunosuppressant use because of an immune-related adverse event.\nThere was one treatment-related death in each cohort: pneumonitis in the NIVO cohort and GI motility disorder because of enteric neuropathy in the NIVO 1 IPI cohort, the latter of which has been reported elsewhere.\nAmong patients who discontinued treatment for any reason other than disease progression, one of 18 patients (5.5%) in the NIVO cohort and two of 28 patients (7.1%) in the NIVO 1 IPI cohort subsequently experienced disease pro- gression.\n\n\n\n\n← Previous Next →"
  },
  {
    "objectID": "Post_JC_Survey.html#discussion",
    "href": "Post_JC_Survey.html#discussion",
    "title": "SoCO Journal Club",
    "section": "Discussion",
    "text": "Discussion\nPaul/Sunandna\n\n\n\nCheckmate 067\n\n\n\n\n\n\n\n\n\nCheckmate-8HW"
  }
]